Cystic-fibrosis patients susceptible to pseudomonas cross-infection

August 16, 2001

N.B Please note that if you are outside North America the embargo for Lancet Press material is 0001 hours UK Time Friday 17th August 2001.

Two research letters in this week's issue of THE LANCET provide new evidence that patients with cystic fibrosis (CF) are susceptible to cross-infection-including superinfection-to the bacterium Pseudomonas aeruginosa.

Chronic colonisation with P aeruginosa occurs in up to 80% of adults with CF, and is associated with increased illness and death. Once a patient with CF acquires a P aeruginosa strain, it has been thought to be unusual for them to acquire a different strain. Martin Walshaw and colleagues from the Regional Adult Cystic Fibrosis Unit, Liverpool, UK, investigated genotypic changes in strains of P aeruginosa in adult patients in their CF clinic. Four adults with CF acquired a new strain (AH), probably as a result of social contact in hospital with patients colonised with the AH strain. The investigators suggest that inpatients with CF who are colonised with P aeruginosa should be separated by strain type, although they acknowledge that this approach (which involves genotyping) has resource implications.

In a second research letter, Andrew Jones and colleagues from the Adult Cystic Fibrosis Centre, Manchester, and Edinburgh University Medical School,UK, did a surveillance study and found that 14% of patients in the Manchester adult clinic had a multiresistant strain which differed from the Liverpool outbreak. The investigators recommend microbiological surveillance in other CF centres.

In an accompanying Commentary (p 522), Duncan Geddes from the Royal Brompton National Heart and Lung Hospital, London, UK, discusses the measures that have been proposed for infection control in CF clinics. He cautions: "Perhaps the most worrying feature of the debate is the effect on the families with CF. There is a real risk of stigmatisation by sputum bacteriology, enhanced anxiety about what may be a relatively benign organism (many adults with CF remain well despite positive cultures of Pseudomonas aeruginosa for decades), and fear of attending a CF centre or any school or social event where another person with CF may be met. There are risks in doing too little but it may be worse to do too much."
-end-
Contact: Dr Martin J Walshaw, Regional Adult Cystic Fibrosis Unit, The Cardiothoracic Centre, Thomas Drive, Liverpool L14 3PE, UK; T) 44-151-228-1616 x2390; F) 44-151-293-2331; E) Martin.Walshaw@CCL-TR.NWEST.NHS.UK

Dr Andrew M Jones, Adult Cystic Fibrosis Centre, Wythenshawe Hospital, Southmoor Road ,Manchester M23 9LT, UK; T) 44-161-795-4567 bleep 4104; F) 44-161-291-2080; E) andmarkj@hotmail.com

Lancet

Related Cystic Fibrosis Articles from Brightsurf:

Treating cystic fibrosis with mRNA therapy or CRISPR
The potential for treating cystic fibrosis (CF) using mRNA therapies or CRISPR gene editing is possible regardless of the causative mutation.

Cystic fibrosis: why so many respiratory complications?
Cystic fibrosis, one of the most common genetic diseases in Switzerland, causes severe respiratory and digestive disorders.

A newly discovered disease may lead to better treatment of cystic fibrosis
Cystic fibrosis is the most frequent severe inherited disorder worldwide.

New treatment kills off infection that can be deadly to cystic fibrosis patients
The findings, which are published in the journal Scientific Reports, show that scientists from Aston University, Mycobacterial Research Group, combined doses of three antibiotics -- amoxicillin and imipenem-relebactam and found it was 100% effective in killing off the infection which is usually extremely difficult to treat in patients with cystic fibrosis.

Cystic fibrosis carriers are at increased risk for cystic fibrosis-related conditions
A University of Iowa study challenges the conventional wisdom that having just one mutated copy of the cystic fibrosis (CF) gene has no effects on a person's health.

Rare mutations drive cystic fibrosis in Caribbean
Cystic Fibrosis (CF) in the Caribbean is dominated by unusual gene mutations not often observed in previously studied CF populations, according to comprehensive genome sequencing led by physician-scientists at UC San Francisco and Centro de Neumología Pediátrica in San Juan.

Cystic fibrosis carriers at increased risk of digestive symptoms
Researchers have found that carriers of the most common genetic variant that causes cystic fibrosis experience some symptoms similar to those of people with cystic fibrosis.

In cystic fibrosis, lungs feed deadly bacteria
A steady supply of its favorite food helps a deadly bacterium thrive in the lungs of people with cystic fibrosis, according to a new study by Columbia researchers.

Cibio knocks out cystic fibrosis
The fight against cystic fibrosis continues, targeting in particular some of the mutations that cause it.

Hypertonic saline may help babies with cystic fibrosis breathe better
Babies with cystic fibrosis may breathe better by inhaling hypertonic saline, according to a randomized controlled trial conducted in Germany and published in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

Read More: Cystic Fibrosis News and Cystic Fibrosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.